Transcription of This document is referenced in USP General Chapter <1121 ...
{{id}} {{{paragraph}}}
Example: marketing
This document is referenced in USP General Chapter <1121 ...
Page 1 of 36 EFFECTIVE DATE 03/30/2020 Nomenclature Guidelines This document is referenced in USP General Chapter <1121> Nomenclature, and will be periodically updated by the USP Expert Committee on Nomenclature and Labeling ( last revision on March 30, 2020) Introduction A consistent and logical approach to naming compendial articles, including small molecule and large molecule drug substances, drug products, excipients, and dietary supplements, is critical to the usefulness and integrity of the United States Pharmacopeia National Formulary (USP NF). To achieve this consistency, standard naming approaches for developing monograph titles appearing in the USP NF are carried out by the Nomenclature and Labeling Expert Committee.
the monograph title (e.g. Acetaminophen and Codeine Phosphate Tablets). o Where the vehicle is therapeutically active or equivalent to another component, the word “and” is used in the monograph title (e.g., Dextrose and Sodium Chloride Injection). • Use of the term “in”:
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: